1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,850 | 10,500 | 06.06. | |
| 9,850 | 10,500 | 05.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.05. | MiNK Therapeutics behandelt ersten Patienten in Phase-2-Studie zu akuter Lungenschädigung | - | Investing.com Deutsch | ||
| 28.05. | MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | 180 | GlobeNewswire (Europe) | First patient dosed marks rapid transition from trial activation to active treatment in patients with acute lung injury from all cause pneumonia meeting Global ARDS criteriaLandmark advances a first-in-class... ► Artikel lesen | |
| 20.05. | MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications | 162 | GlobeNewswire (Europe) | agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved... ► Artikel lesen | |
| 15.05. | Earnings Call Transkript: MiNK Therapeutics zeigt in Q1 2026 strategische Fortschritte | 6 | Investing.com Deutsch | ||
| 15.05. | Transcript: MiNK Therapeutics Q1 2026 Earnings Conference Call | 2 | Benzinga.com | ||
| 15.05. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.05. | MiNK Therapeutics starts phase 2 trial for lung injury therapy | 1 | Investing.com | ||
| 15.05. | MiNK Therapeutics GAAP EPS of -$0.57 beats by $0.20 | 2 | Seeking Alpha | ||
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 15.05. | MiNK Therapeutics startet Phase-2-Studie für Therapie gegen akute Lungenschädigung | 1 | Investing.com Deutsch | ||
| 15.05. | MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation | 232 | GlobeNewswire (Europe) | Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase... ► Artikel lesen | |
| 14.05. | MiNK Therapeutics and First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness | 316 | GlobeNewswire (Europe) | Randomized Phase 2 trial evaluates off-the-shelf invariant natural killer T (iNKT) cell therapy in patients with acute lung injury and hypoxemic respiratory failure Study initiates in Lviv, Ukraine... ► Artikel lesen | |
| 12.05. | MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 | 1 | GlobeNewswire (USA) | ||
| 08.05. | MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs | 2 | GlobeNewswire (USA) | ||
| 17.04. | MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer | 183 | GlobeNewswire (Europe) | First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset... ► Artikel lesen | |
| 03.04. | MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 02.04. | MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy | 3 | GlobeNewswire (USA) | ||
| 31.03. | MiNK Therapeutics, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 31.03. | MiNK Therapeutics GAAP EPS of -$0.56 beats by $0.12 | 6 | Seeking Alpha | ||
| 31.03. | MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum | 222 | GlobeNewswire (Europe) | ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000-300,000 patients annually in US/EUC-Further Consortium collaboration adds to growing... ► Artikel lesen | |
| 27.03. | MiNK Therapeutics: Aktie springt nach Klarstellung zu Gesprächen über Kombinationsstudien | 8 | Investing.com Deutsch |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 77,05 | -1,34 % | BioNTech und BMS melden neue Daten für Lungenkrebskandidat Pumitamig | BioNTech SE und Bristol Myers Squibb haben auf dem ASCO-Jahreskongress in Chicago erste globale Phase-2-Daten für den bispezifischen Immunmodulator Pumitamig in Kombination mit Chemotherapie bei fortgeschrittenem... ► Artikel lesen | |
| BB BIOTECH | 45,850 | -0,86 % | BB Biotech: "Wachstumsstarke Mid- und Small Caps bilden das Rückgrat unseres Portfolios": Mehr Einzelwerte und ... | ||
| VALNEVA | 2,331 | -0,64 % | Valneva im Höhenflug: Das Signal das die meisten Anleger noch nicht kennen - Meine Einschätzung für die neue Börsenwoche | ||
| NOVAVAX | 8,080 | -1,70 % | NOVAVAX INC: Stabilität vor der nächsten Bewegung | ||
| OCUGEN | 1,118 | +0,18 % | Ocugen, Inc. - 8-K, Current Report | ||
| VIKING THERAPEUTICS | 24,650 | -0,20 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| INFLARX | 1,594 | -0,44 % | InflaRx NV im freien Fall: Steht die Aktie vor einem Kursdesaster? - Meine Strategie für die kommende Handelswoche! | ||
| INTELLIA THERAPEUTICS | 11,240 | -4,26 % | Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution | ||
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,232 | -0,85 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,800 | +0,88 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,235 | -1,56 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| CARDIOL THERAPEUTICS | 0,989 | +2,17 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
30.04.2026 / 13:07 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| GERON | 1,039 | +1,86 % | Geron Corporation Reports First Quarter 2026 Financial Results and Recent Business Highlights | Achieved $51.8 million in RYTELO- (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating... ► Artikel lesen | |
| BASILEA | 53,90 | +0,37 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen |
MINK THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +8,82 % bei einem Aktienkurs von 11,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.